Cargando…
Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
Nirmatrelvir boosted with Ritonavir is the recommended and preferred treatment for COVID-19. Because real-world evidence of Nirmatrelvir’s antiviral activity against the Omicron variation is minimal, our study focuses on recent papers suggesting the use of Ritonavir-boosted Nirmatrelvir in the real...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949877/ https://www.ncbi.nlm.nih.gov/pubmed/36845759 http://dx.doi.org/10.1097/MS9.0000000000000169 |